Vertex Pharmaceuticals Incorporated Share Price

Equities

VRTX

US92532F1003

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 24/04/2024 BST 5-day change 1st Jan Change
400.8 USD -1.02% Intraday chart for Vertex Pharmaceuticals Incorporated +1.67% -1.51%
Sales 2024 * 10.72B 861B Sales 2025 * 11.74B 943B Capitalization 105B 8,401B
Net income 2024 * 3.86B 310B Net income 2025 * 4.44B 357B EV / Sales 2024 * 8.18 x
Net cash position 2024 * 16.91B 1,358B Net cash position 2025 * 21.28B 1,708B EV / Sales 2025 * 7.1 x
P/E ratio 2024 *
27.2 x
P/E ratio 2025 *
23.7 x
Employees 5,400
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.89%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Vertex Pharmaceuticals Incorporated

1 day-1.02%
1 week+1.67%
Current month-4.13%
1 month-3.58%
3 months-8.86%
6 months+9.00%
Current year-1.51%
More quotes
1 week
391.01
Extreme 391.01
406.86
1 month
391.01
Extreme 391.01
421.45
Current year
391.01
Extreme 391.01
448.40
1 year
316.43
Extreme 316.43
448.40
3 years
176.36
Extreme 176.36
448.40
5 years
164.07
Extreme 164.07
448.40
10 years
62.41
Extreme 62.405
448.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 31/01/17
Chairman 68 07/07/09
Director of Finance/CFO 55 09/04/19
Members of the board TitleAgeSince
Director/Board Member 68 07/06/17
Chairman 68 07/07/09
Director/Board Member 64 31/12/97
More insiders
Date Price Change Volume
24/04/24 400.8 -1.02% 786,339
23/04/24 404.9 +1.25% 1,070,343
22/04/24 399.9 +1.43% 1,393,886
19/04/24 394.3 +0.20% 1,342,138
18/04/24 393.5 +0.10% 949,091

Delayed Quote Nasdaq, April 24, 2024 at 09:00 pm

More quotes
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
404.9 USD
Average target price
460.3 USD
Spread / Average Target
+13.69%
Consensus